Effects of Long-Term Methotrexate, Infliximab, and Tocilizumab Administration on Bone Microarchitecture and Tendon Morphology in Healthy Wistar Rats.
bone mineral density
infliximab
methotrexate
rheumatic diseases
tocilizumab
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
26 Apr 2021
26 Apr 2021
Historique:
entrez:
31
5
2021
pubmed:
1
6
2021
medline:
1
6
2021
Statut:
epublish
Résumé
Objective Rheumatic diseases are associated with bone loss, both systemic and periarticular, and tendon abnormalities. The aim of this study is to examine the effect of three antiarthritic drugs, methotrexate, an anti-folate metabolite; infliximab, a Tumor Necrosis Factor-alpha (TNF-α) inhibitor; and tocilizumab, an antibody against Interleukin-6 (IL-6) receptor, on bone microarchitecture and tendon morphology in the absence of an inflammatory state. Materials and methods Thirty-five, 8- to 9-week-old, male, Wistar rats were randomly allocated into five groups: negative control (CTRL), vehicle (VEH), methotrexate (MTX), infliximab (INFX), and tocilizumab (TCZ). After 8 weeks of antiarthritic drug intraperitoneal administration, animals were euthanized and rat tibiae and patellar tendons were histologically examined. Results All sections exhibited normal bone microarchitecture. Histological scores in all groups corresponded to normal bone mineral density. No no apparent differences in tenocyte morphology and architecture of collagen fibers were observed. Conclusions The results of this study indicate that long-term administration of methotrexate, infliximab, and tocilizumab had no effect on bone microarchitecture and tendon morphology in rats in the absence of an inflammatory condition.
Identifiants
pubmed: 34055540
doi: 10.7759/cureus.14696
pmc: PMC8153088
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e14696Informations de copyright
Copyright © 2021, Poutoglidou et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Int Med Res. 2006 Nov-Dec;34(6):624-31
pubmed: 17294994
Radiology. 1997 Feb;202(2):543-7
pubmed: 9015088
Curr Biol. 2001 Aug 7;11(15):R592-5
pubmed: 11516963
Calcif Tissue Int. 1999 Feb;64(2):100-1
pubmed: 9914314
Rheumatology (Oxford). 2005 Dec;44(12):1546-8
pubmed: 16263785
Bone. 1995 Feb;16(2):215-21
pubmed: 7756050
Knee Surg Sports Traumatol Arthrosc. 2001 Sep;9(5):322-6
pubmed: 11685366
Rheumatol Int. 2003 Sep;23(5):231-5
pubmed: 14504915
Osteoporos Int. 2018 Jun;29(6):1263-1275
pubmed: 29546507
Joint Bone Spine. 2011 Mar;78(2):188-93
pubmed: 20621536
Arthritis Rheumatol. 2016 Feb;68(2):312-22
pubmed: 26473401
Arzneimittelforschung. 1999 Jan;49(1):38-43
pubmed: 10028378
Ann Rheum Dis. 2002 Nov;61(11):1007-11
pubmed: 12379525
Rheumatology (Oxford). 2014 May;53(5):900-3
pubmed: 24441151
Clin Interv Aging. 2015 Aug 05;10:1245-53
pubmed: 26345380
Clin Exp Immunol. 2014 Feb;175(2):172-80
pubmed: 24028747
Osteoarthritis Cartilage. 2006 Jan;14(1):13-29
pubmed: 16242352
Ann Rheum Dis. 2006 Nov;65(11):1495-9
pubmed: 16606653
J Orthop Res. 2010 Aug;28(8):1071-7
pubmed: 20127972
Rheumatology (Oxford). 2012 Jul;51(7):1246-60
pubmed: 22378717
Reprod Sci. 2016 May;23(5):662-9
pubmed: 26566855
Bone. 2004 Nov;35(5):1200-7
pubmed: 15542046
Clin Rheumatol. 2020 Jan;39(1):167-175
pubmed: 31522318
Ann Rheum Dis. 2004 Dec;63(12):1576-80
pubmed: 15547081
Med Arch. 2016 Apr;70(2):101-3
pubmed: 27147781
Osteoporos Int. 1997;7 Suppl 3:S217-22
pubmed: 9536336
Basic Clin Pharmacol Toxicol. 2013 May;112(5):335-40
pubmed: 23167806
Pharmacol Rep. 2015 Feb;67(1):102-14
pubmed: 25560583
Curr Opin Rheumatol. 2018 Jan;30(1):59-64
pubmed: 29016371